|
KMID : 1189120080050020111
|
|
대한의학유전학회지
2008 Volume.5 No. 2 p.111 ~ p.118
|
|
|
A Cost-Benefit Analysis of Neonatal Screening Tests for Maple Syrup Urine Disease, Homocystinuria, Galactosemia, and Congenital Adrenal Hyperplasia
|
|
Park Shin-Young
Kim Dong-Il
Lee Dong-Hwan
|
|
|
Abstract
|
|
|
Purpose: Neonatal screening test is used increasingly in early diagnosis of inborn errors of metabolism (IEM) in the hope of avoiding the severe developmental delay, acute illness, and death that may result from these diseases. In this study, a cost-benefit analysis was performed on the neonatal screening of maple syrup urine disease, homocystinuria, galactosemia and congenital adrenal hyperplasia in Korea.
Methods: This study included 1,259,220 Korean newborns from January 2005 to December 2007, who were screened for maple syrup urine disease, homocystinuria, galactosemia and congenital adrenal hyperplasia. We calculated and compared the total costs in case when these four screening tests were implemented, and when not.
Results: If the neonatal screening of maple syrup urine disease, homocystinuria, galactosemia and congenital adrenal hyperplasia is implemented, there were no benefits in maple syrup urine disease and homocystinuria due to its low prevalance, each of benefits exceed costs at a ratio was 0.573:1 and 0.675:1. But benefits far exceed costs at a ratio of 4.162:1 in galactosemia, and 2.923:1 in congenital adrenal hyperplasia and totally 2.005:1.
Conclusion: Neonatal screening of maple syrup urine disease, homocystinuria, galactosemia and congenital adrenal hyperplasia is financially beneficial, although we excluded other values such as quality of life in this study.
|
|
|
KEYWORD
|
|
|
Neonatal Screening Test, Cost-benefit, Efficacy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|